1. Ablation of TRPV1 Abolishes Salicylate-Induced Sympathetic Activity Suppression and Exacerbates Salicylate-Induced Renal Dysfunction in Diet-Induced Obesity.
- Author
-
Zhong B, Ma S, and Wang DH
- Subjects
- Animals, Baroreflex drug effects, Disease Models, Animal, Energy Metabolism drug effects, Gene Deletion, Glomerular Filtration Rate drug effects, Hemodynamics drug effects, Inflammation Mediators metabolism, Insulin Resistance, Kidney innervation, Kidney metabolism, Kidney Diseases metabolism, Kidney Diseases physiopathology, Kidney Diseases prevention & control, Mice, Inbred C57BL, Mice, Knockout, Obesity complications, Obesity metabolism, Obesity physiopathology, Sympathetic Nervous System metabolism, Sympathetic Nervous System physiopathology, TRPV Cation Channels genetics, Mice, Cyclooxygenase Inhibitors toxicity, Diet, High-Fat, Kidney drug effects, Kidney Diseases chemically induced, Obesity drug therapy, Sodium Salicylate toxicity, Sympathetic Nervous System drug effects, TRPV Cation Channels deficiency
- Abstract
Sodium salicylate (SA), a cyclooxygenase inhibitor, has been shown to increase insulin sensitivity and to suppress inflammation in obese patients and animal models. Transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel expressed in afferent nerve fibers. Cyclooxygenase-derived prostaglandins are involved in the activation and sensitization of TRPV1. This study tested whether the metabolic and renal effects of SA were mediated by the TRPV1 channel. Wild-type (WT) and TRPV1
-/- mice were fed a Western diet (WD) for 4 months and received SA infusion (120mg/kg/day) or vehicle for the last 4 weeks of WD feeding. SA treatment significantly increased blood pressure in WD-fed TRPV1-/- mice ( p < 0.05) but not in WD-fed WT mice. Similarly, SA impaired renal blood flow in TRPV1-/- mice ( p < 0.05) but not in WT mice. SA improved insulin and glucose tolerance in both WT and TRPV1-/- mice on WD (all p < 0.05). In addition, SA reduced renal p65 and urinary prostaglandin E2, prostaglandin F1α, and interleukin-6 in both WT and TRPV1-/- mice (all p < 0.05). SA decreased urine noradrenaline levels, increased afferent renal nerve activity, and improved baroreflex sensitivity in WT mice (all p < 0.05) but not in TRPV1-/- mice. Importantly, SA increased serum creatinine and urine kidney injury molecule-1 levels and decreased the glomerular filtration rate in obese WT mice (all p < 0.05), and these detrimental effects were significantly exacerbated in obese TRPV1-/- mice (all p < 0.05). Lastly, SA treatment increased urine albumin levels in TRPV1-/- mice ( p < 0.05) but not in WT mice. Taken together, SA-elicited metabolic benefits and anti-inflammatory effects are independent of TRPV1, while SA-induced sympathetic suppression is dependent on TRPV1 channels. SA-induced renal dysfunction is dependent on intact TRPV1 channels. These findings suggest that SA needs to be cautiously used in patients with obesity or diabetes, as SA-induced renal dysfunction may be exacerbated due to impaired TRPV1 in obese and diabetic patients.- Published
- 2021
- Full Text
- View/download PDF